8-K: Viridian Therapeutics Reports Positive Phase 3 Data and Strong Financial Position

Viridian Therapeutics announces positive topline Phase 3 data for veligrotug in thyroid eye disease and reports a strong cash position of $717.6 million.

Summary

• Viridian Therapeutics reported positive topline Phase 3 data for veligrotug in patients with active and chronic thyroid eye disease (TED).
• The company is on track to submit a Biologics License Application (BLA) for veligrotug in the second half of 2025.
• Phase 3 clinical trials REVEAL-1 and REVEAL-2, assessing VRDN-003 in active and chronic TED, are progressing as planned with topline data expected in the first half of 2026.
• Proof-of-concept clinical data for VRDN-006 in healthy volunteers is anticipated in the third quarter of 2025.
• VRDN-008 is expected to have additional preclinical data in 2025, with an Investigational New Drug (IND) submission planned for year-end 2025.
• Radhika Tripuraneni, M.D., has been appointed as Chief Medical Officer.
• The company's cash position as of December 31, 2024, was $717.6 million, providing a cash runway into the second half of 2027.
• Research and development expenses were $238.3 million for the year ended December 31, 2024.
• The company's net loss was $269.9 million for the year ended December 31, 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical trial results, a solid financial position, and advancement of multiple programs. The appointment of a new CMO also adds to the positive sentiment.

Positives

• Positive topline Phase 3 data for veligrotug in active and chronic TED.
• Veligrotug demonstrated a differentiated clinical profile with rapid onset and significant reduction in diplopia.
• BLA submission for veligrotug is on track for the second half of 2025.
• REVEAL-1 and REVEAL-2 trials are progressing as planned with topline data expected in the first half of 2026.
• Strong cash position of $717.6 million provides a cash runway into the second half of 2027.

Negatives

• The company reported a net loss of $269.9 million for the year ended December 31, 2024, compared with $237.7 million for the same period last year.
• Research and development expenses increased to $238.3 million during the year ended December 31, 2024, compared to $159.8 million during the year ended December 31, 2023.

Risks

• The company's forward-looking statements are subject to material risks and uncertainties, including the potential utility, efficacy, and safety of its product candidates.
• Clinical trial results may not be representative of future trials.
• Regulatory delays could impact clinical programs.
• Competition from other therapies or products could affect market success.
• Manufacturing risks could impact product development and commercialization.

Future Outlook

Viridian anticipates several key milestones, including BLA submissions for veligrotug and VRDN-003, MAA submission for veligrotug, IND submission for VRDN-008, and topline data readouts from REVEAL-1 and REVEAL-2. The company believes its current cash position will fund operations into the second half of 2027.

Management Comments

• We made tremendous progress in 2024 which was capped off by the positive and better-than-expected pivotal data for our lead TED program veligrotug in active and chronic TED, and advancing towards the clinic with an IND submission for our lead FcRn inhibitor program VRDN-006, said Steve Mahoney, Viridians President and CEO.
• The veligrotug BLA submission is on track for 2H 2025 and our early commercial preparations are underway.
• In the new start TED market, we are excited about the potential for veligrotug to become the treatment-of-choice for patients.

Industry Context

Viridian is focused on developing best-in-class medicines for serious and rare diseases, particularly in thyroid eye disease (TED) and autoimmune diseases. The company's FcRn inhibitor portfolio targets a market projected to reach close to $10 billion by 2030, with potential applications in numerous autoimmune conditions.

Comparison to Industry Standards

• Viridian's veligrotug is being developed as an IV treatment-of-choice for active and chronic TED, competing with Horizon Therapeutics' Tepezza, the current market leader.
• VRDN-003 is designed as a subcutaneous, half-life extended anti-IGF-1R antibody, aiming to provide a more convenient at-home administration option compared to IV infusions.
• Viridian's FcRn inhibitor portfolio, including VRDN-006 and VRDN-008, targets a broad array of autoimmune diseases, similar to efforts by companies like argenx (Vyvgart) and UCB (Rystiggo) in myasthenia gravis and other indications.
• The company's focus on developing potential best-in-class therapies aligns with the industry trend of seeking differentiated clinical profiles and improved patient convenience.

Management Changes

Related Party Transactions

• The company reported collaboration revenue related to a related party of $302,000 for the year ended December 31, 2024.

Stakeholder Impact

• Shareholders: Positive clinical trial results and strong financial position could lead to increased shareholder value.
• Patients: Successful development of veligrotug and VRDN-003 could provide new treatment options for thyroid eye disease.
• Employees: Continued growth and progress could lead to job security and opportunities.
• Customers: Potential for new and improved therapies in the future.

Next Steps

• Submit a BLA for veligrotug in the second half of 2025.
• Advance REVEAL-1 and REVEAL-2 trials and report topline data in the first half of 2026.
• Obtain proof-of-concept data for VRDN-006 in Q3 2025.
• Generate additional preclinical data for VRDN-008 in 2025 and submit an IND by year-end 2025.

Key Dates